Interesting. I've noticed that I have been getting marketing emails from Thorne starting a couple months ago . Thanks for flagging . The CEO has an interesting background and seems legit based on what he posted on Linkedin (if that's accurate) and he's been with the company a long time. He's also the largest shareholder after the three institutions that own 70%.
I’m not a Huberman listener, but I have been a user of Thorne products for a while (I have also gotten deep into fragrances in recent years, but that's a different story). I've been watching THRN since it IPO'd, and although I am rooting for management I cannot get myself bullish on either the business or the equity. Because of the very low levels of regulation and the fact that a lot of these compounds are inexpensive to synthesize the barriers to entry are incredibly low, even for those with premium product formulations. It is hard for me to see a way for Thorne to maintain premium pricing as it scales. The fact that 2022 top line growth is looking like it will be half of what it was in 2021 might confirm this worry.
I will start to get bullish on the premium side of the supplements industry if/when primary care physicians start relying on supplements as a core part of their care. The AMA has been skeptical of supplements for a variety of reasons, quality control being one of their top concerns. Either Thorne on its own, or a consortium of premium, high-quality supplements manufacturers together, should attempt a push in into the medical market with a menu of suggested primary care applications, as well as a voluntary, third party verified regulatory scheme, to develop this end of the market.
This is rather refreshing I don’t know much about fragrance or luxury. But I think one of its supplier perhaps could have some moat in their business. It’s IFF. Personally I like it better than Givaudan
Interesting. I've noticed that I have been getting marketing emails from Thorne starting a couple months ago . Thanks for flagging . The CEO has an interesting background and seems legit based on what he posted on Linkedin (if that's accurate) and he's been with the company a long time. He's also the largest shareholder after the three institutions that own 70%.
Rhonda Patrick also mentioned Thorne a bunch of times, though I don't think it was ever sponsored, just her own preference.
That Jeremy Fragrance video is amazing -- almost did a spit-take in the middle
Yesssss, I love your random obsessions with stuff that isn't semi as much as your semi stuff, sometimes more!
nice post!
I’m not a Huberman listener, but I have been a user of Thorne products for a while (I have also gotten deep into fragrances in recent years, but that's a different story). I've been watching THRN since it IPO'd, and although I am rooting for management I cannot get myself bullish on either the business or the equity. Because of the very low levels of regulation and the fact that a lot of these compounds are inexpensive to synthesize the barriers to entry are incredibly low, even for those with premium product formulations. It is hard for me to see a way for Thorne to maintain premium pricing as it scales. The fact that 2022 top line growth is looking like it will be half of what it was in 2021 might confirm this worry.
I will start to get bullish on the premium side of the supplements industry if/when primary care physicians start relying on supplements as a core part of their care. The AMA has been skeptical of supplements for a variety of reasons, quality control being one of their top concerns. Either Thorne on its own, or a consortium of premium, high-quality supplements manufacturers together, should attempt a push in into the medical market with a menu of suggested primary care applications, as well as a voluntary, third party verified regulatory scheme, to develop this end of the market.
This is rather refreshing I don’t know much about fragrance or luxury. But I think one of its supplier perhaps could have some moat in their business. It’s IFF. Personally I like it better than Givaudan